EA201390197A1 - Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого - Google Patents

Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого

Info

Publication number
EA201390197A1
EA201390197A1 EA201390197A EA201390197A EA201390197A1 EA 201390197 A1 EA201390197 A1 EA 201390197A1 EA 201390197 A EA201390197 A EA 201390197A EA 201390197 A EA201390197 A EA 201390197A EA 201390197 A1 EA201390197 A1 EA 201390197A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hmgb1
kit
fecal
intestine
definition
Prior art date
Application number
EA201390197A
Other languages
English (en)
Inventor
Сальваторе Куккьяра
Лаура Стронати
Роберта Витали
Original Assignee
Д.М.Г. Италия Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Д.М.Г. Италия Срл filed Critical Д.М.Г. Италия Срл
Publication of EA201390197A1 publication Critical patent/EA201390197A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Предложен неинвазивный способ измерения воспалительного состояния кишечника у человека по присутствию белка HMGB1 в экстрактах фекалий и участию такого белка в патогенезе хронических воспалительных заболеваний кишечника, в частности болезни Крона (БК) и язвенного колита (ЯК), включающий определение присутствия HMGB1 в фекалиях с помощью Вестерн-блота или ИФА с применением соответствующего антиген-антитела. Изобретение также относится к колориметрическому набору для осуществления такого способа.
EA201390197A 2010-08-05 2011-08-01 Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого EA201390197A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Publications (1)

Publication Number Publication Date
EA201390197A1 true EA201390197A1 (ru) 2013-06-28

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390197A EA201390197A1 (ru) 2010-08-05 2011-08-01 Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого

Country Status (14)

Country Link
US (1) US20130137123A1 (ru)
EP (1) EP2601525A1 (ru)
JP (1) JP2013534313A (ru)
CN (1) CN103069276A (ru)
AU (1) AU2011287193B2 (ru)
BR (1) BR112013002145A2 (ru)
CA (1) CA2807107C (ru)
CL (1) CL2013000223A1 (ru)
EA (1) EA201390197A1 (ru)
IL (1) IL223845A (ru)
IT (1) IT1406051B1 (ru)
MX (1) MX2013001327A (ru)
PE (1) PE20131062A1 (ru)
WO (1) WO2012017466A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
SG11201507226YA (en) 2013-03-15 2015-10-29 Protagonist Therapeutics Inc Hepcidin analogues and uses therof
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
BR112017001010A2 (pt) 2014-07-17 2017-11-14 Protagonist Therapeutics Inc inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018089693A2 (en) * 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
DK3622082T3 (da) 2017-05-12 2023-06-12 Evonik Operations Gmbh Fremgangsmåde til påvisning af c. perfringens-inducerede sygdomme i en fugleflok
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
RU2770104C2 (ru) * 2018-03-02 2022-04-14 Эвоник Оперейшенс ГмбХ Способ in vitro выявления недостаточности кишечного барьера у животных путем определения овотрансферрина
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
CN118005736A (zh) 2020-01-15 2024-05-10 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0964250B1 (en) * 1996-07-17 2007-06-27 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
EP2295976A1 (en) * 2003-03-08 2011-03-16 Auvation Ltd Markers for colorectal cancer
KR20070090890A (ko) * 2004-10-22 2007-09-06 메디뮨 인코포레이티드 Ｈｍｇｂ1에 대한 고 친화성 항체 및 이의 사용 방법
EP2105447A4 (en) * 2006-12-20 2010-05-05 Shino Test Corp ANTIBODIES OF AVIAN ORIGIN CAPABLE OF SPECIFICALLY BINDING TO HUMAN HMGB1, METHOD OF IMMUNOLOGICAL DETERMINATION FOR HUMAN HMGB1, AND IMMUNOLOGICAL DETERMINATION REAGENT FOR HUMAN HMGB1
AU2008283077A1 (en) * 2007-08-02 2009-02-05 Ith Immune Therapy Holdings Ab Diagnosis, staging and monitoring of inflammatory bowel disease
KR20100124326A (ko) * 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커

Also Published As

Publication number Publication date
BR112013002145A2 (pt) 2016-05-24
AU2011287193B2 (en) 2015-08-13
MX2013001327A (es) 2013-03-08
WO2012017466A8 (en) 2013-07-11
US20130137123A1 (en) 2013-05-30
CA2807107A1 (en) 2012-02-09
ITRM20100442A1 (it) 2012-02-06
AU2011287193A1 (en) 2013-06-13
IL223845A (en) 2016-06-30
CL2013000223A1 (es) 2014-03-28
JP2013534313A (ja) 2013-09-02
PE20131062A1 (es) 2013-10-16
CA2807107C (en) 2017-01-03
WO2012017466A1 (en) 2012-02-09
CN103069276A (zh) 2013-04-24
IT1406051B1 (it) 2014-02-06
EP2601525A1 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
EA201390197A1 (ru) Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого
BR112012007365A2 (pt) proteínas de ligação à il-1
UA109633C2 (uk) Антитіло людини проти тканинного фактора
DOP2011000274A (es) Proteinas de union a il-17
BR112012028920A2 (pt) formulações de anticorpo de alta concentração
EA201000424A1 (ru) Антитела к il-23
WO2010060102A3 (en) Prediction and prevention of preeclampsia
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201992614A3 (ru) Il-18-связывающие молекулы
FR2896588B1 (fr) Methode de diagnostic in vitro de reponse immunitaire autoimmune par detection d'anticorps diriges contre l'antigene pentraxine 3.
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201390310A1 (ru) Фармацевтические композиции, содержащие рифаксимин, способы их получения и способ лечения кишечного заболевания
WO2011156734A3 (en) Method of characterizing vascular diseases
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
BRPI0916101A2 (pt) "método para determinar o estágio de uma gravidez, dispositivo adaptado para detectar os níveis/a quantidade de hpl ou de um fragmento do mesmo em uma amostra de fluido corpóreo derivado de uma fêmea humana, kit e uso de um anticorpo anti-hpl"
BR112013000796A2 (pt) Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
EA201792669A1 (ru) Igfbp3 и его применение
López-Colom et al. I-FABP, Pig-MAP and TNF-α as biomarkers for monitoring gut-wall integrity in front of Salmonella Typhimurium and ETEC K88 infection in a weaned piglet model
BRPI0712273A2 (pt) Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
EA201290977A1 (ru) Гуманизированные антитела к il-25
EP1769244A4 (en) DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES
WO2011112670A3 (en) Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
BR112012028010A2 (pt) anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
PL408905A1 (pl) Nowy związek, sposób jego otrzymywania, roztwór farmaceutyczny zawierający nowy związek, sposób określania obecności choroby nowotworowej, zestaw do wykrywania nowotworów oraz zastosowanie hydrolizy nowego związku do wykrywania nowotworów